Melanoma

Jergens® Skincare Celebrates its Second Annual Glow Day with New Product Innovation and Commitment to Skin Health Education

Retrieved on: 
Wednesday, March 20, 2024
Health, Skin care, Skin Cancer Foundation, Personality, Education, Face, Skin cancer, Patient, Tanning, Social media, Skin, Love, Melanoma, Collection, Cosmetics

CINCINNATI, March 20, 2024 /PRNewswire/ -- Jergens® Natural Glow® Skincare is kicking off the Spring season with its second annual Glow Day, which marks that special time of year where we officially start to prepare our skin for sunnier moments ahead! With a recent resurgence in UV tanning, Glow Day is also the perfect time to focus on skin health and find a UV-free solution that can achieve natural-looking color without causing damage to skin.

Key Points: 
  • CINCINNATI, March 20, 2024 /PRNewswire/ -- Jergens® Natural Glow® Skincare is kicking off the Spring season with its second annual Glow Day, which marks that special time of year where we officially start to prepare our skin for sunnier moments ahead!
  • With a recent resurgence in UV tanning, Glow Day is also the perfect time to focus on skin health and find a UV-free solution that can achieve natural-looking color without causing damage to skin.
  • "We want Glow Day to be all about embracing the knowledge that empowers confidence and highlighting effective products that are available in multiple formulations so consumers can find their perfect match."
  • The new Natural Glow Sun Drops joins the ranks of other cult-favorite Natural Glow products, including the Natural Glow Daily Moisturizer, Natural Glow + Firming Daily Moisturizer, and Instant Sun Sunless Tanning Mousse, which are all available on Amazon.

Trialbee's Jamie Goldfarb to Lead Discussion on Defining Success and Enhancing Collaboration in Clinical Trials at Patients as Partners in Clinical Research Conference

Retrieved on: 
Thursday, March 14, 2024
Honey, Goldfarb, Patient, Success, Partner, Food and Drug Administration, ROI, Digital, TIL, Pharmacy, GSK, Research, Participation, National Cancer Institute, Cancer, Medidata Solutions, Ecosystem, Melanoma, Food, FDA, Process optimization, Fireside chats, Pharmaceutical industry

CHAPEL HILL, N.C. and MALMÖ, Sweden, March 14, 2024 /PRNewswire-PRWeb/ -- Trialbee, the global leader in technology-driven patient recruitment for clinical trials, is honored that Director of Patient Recruitment Strategy Jamie Goldfarb will take center stage at the Patients as Partners in Clinical Research on March 20-22, in Philadelphia, PA.

Key Points: 
  • The session aims to strengthen relationships among sites, sponsors, and patients to deepen understanding and engagement.
  • "Many patients aren't aware that clinical trials present viable treatment opportunities, and if they do, their needs are often overlooked," Goldfarb said.
  • "By actively listening to patients, sponsors can gain invaluable insights and perspectives that lead to medical advances and improve countless lives."
  • The Patients as Partners in Clinical Research conference offers a unique opportunity to hear from pharmaceutical research and development leaders, Food and Drug Administration (FDA) representatives, and patient advocates on how patient involvement drives greater efficiencies in clinical research.

EQS-News: DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Retrieved on: 
Wednesday, March 13, 2024
Therapy, FDA, Patent, Bile, Spacecraft, Lung, GLP, Breast, Reactive oxygen species, Patient, Survival, Cell death, Melanoma, Pharmaceutical industry

DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY

Key Points: 
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    The issuer is solely responsible for the content of this announcement.
  • DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
    Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no.
  • 11,890,350 (‘350) by the United States Patent and Trademark Office (USPTO), broadly covering its breakthrough AccuTOX® technology.
  • This patent marks the fourth granted US patent in Defence’s ever-growing patent portfolio, which currently incudes seven published patent families.

Phase 1 onCARlytics solid tumour trial advances to combination arm treatment

Retrieved on: 
Monday, March 11, 2024
Therapy, Amgen, Safety, CD19, Breast, ASX, Ovary, Patient, OASIS, IMU, Blinatumomab, Melanoma, Vaccine

Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.

Key Points: 
  • Known as OASIS, the first-in-class clinical trial is targeting adult patients with advanced or metastatic solid tumours, and aims to evaluate the safety and efficacy of two routes of administration, intratumoral (IT) injection and intravenous (IV) infusion, either alone, or in combination with blinatumomab.
  • The trial is titled: “A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors.” See https://clinicaltrials.gov/study/NCT06063317
    The combination arm of the study will see onCARlytics combined with CD19 targeting bispecific monoclonal antibody blinatumomab (marketed as Blincyto® by Amgen which currently is specifically approved only for liquid blood cancers).
  • onCARlytics has the potential to target and eradicate solid tumours that otherwise cannot be treated with Blincyto® therapy alone and will represent a paradigm shift in solid tumour treatment.
  • OASIS is a dose escalation trial that will be conducted across multiple sites across the United States, with 52 patients proposed to take part in the trial.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Therapy, EDT, Head, CD3, SAN, Investigational New Drug, Cancer, EGFR, Research, Biotechnology, Partnering, TCE, Epithelial cell adhesion molecule, Investment, Melanoma, FDA, Amgen, Therapeutic index, Food, Camptothecin, Gastrointestinal tract, Bladder cancer, Drug discovery, CRC, ADC, Bristol Myers Squibb, BMS, Safety, Kidney, Cytokine, Webcast, Tumor microenvironment, PDT, Patient, Workforce, IND, Trial of the century, Colorectal cancer, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points: 
  • Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
  • In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
  • General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Retrieved on: 
Monday, March 11, 2024
NSCLC, Lung cancer, Disease, MAPK, MEK, Patient, Cancer, Melanoma, Pharmaceutical industry

CAMBRIDGE, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in the Phase 2a portion of its Phase 1/2a clinical trial of IMM-1-104, its lead program. IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of MEK in the MAPK pathway with once-daily oral dosing.

Key Points: 
  • - Phase 2a portion of Phase 1/2a clinical trial will evaluate IMM-1-104 as monotherapy in PDAC, non-small cell lung cancer (NSCLC) and melanoma, and as combination therapy in PDAC -
    CAMBRIDGE, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the first patient has been dosed in the Phase 2a portion of its Phase 1/2a clinical trial of IMM-1-104, its lead program.
  • IMM-1-104 is designed to provide universal-RAS activity through deep cyclic inhibition of MEK in the MAPK pathway with once-daily oral dosing.
  • “The Phase 2a portion includes both monotherapy and combination arms, all in tumor types where we believe IMM-1-104 has the greatest potential to make a positive impact.
  • We look forward to sharing our topline Phase 1 data this month, and then reporting initial results from multiple arms of our Phase 2a later in 2024, which is shaping up to be a data-rich year for our company.”
    The Phase 2a portion of the Phase 1/2a clinical trial of IMM-1-104 is expected to include approximately 150 patients in five arms at our recommended Phase 2 dose of 320 mg once daily.

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
Research, AbbVie, Sale, Carcinoma, Lung cancer, Webcast, Anal cancer, Acute myeloid leukemia, Trial of the century, Melanoma, Head, Neck, SCLC, SCCHN, GAAP, ADAM, B7, Therapy, NSCLC, Syndrome, CD123, ID, AACR, Conference, Safety, Enoblituzumab, ImmunoGen, Clinical trial, Half-life, IND, Conference call, Docetaxel, ASCO, Telephone, Cancer, Spacecraft, HEAT, ADAM9, ADC, Society, Patient, Pharmaceutical industry

ET

Key Points: 
  • ET
    ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
  • “We expect that 2024 will be an important year for MacroGenics, with multiple pipeline advancements anticipated," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
  • MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024
Therapy, Research, Arm, Immunotherapy, Forecasting, Therapeutic index, SITC, AACR, Society, Kidney cancer, Phenotype, Tumor microenvironment, Non-Hodgkin lymphoma, Patient, Cancer, Melanoma, Pharmaceutical industry

WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • “Werewolf made considerable progress in 2023, setting up 2024 as a year of execution across our pipeline,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.
  • Financial Results for the Fourth Quarter and Full Year 2023:
    Cash position: As of December 31, 2023, cash and cash equivalents were $134.3 million, compared to $129.3 million as of December 31, 2022.
  • Net loss: Net loss was $12.0 million for the fourth quarter of 2023, compared to $11.9 million for the same period in 2022.
  • Net loss was $37.4 million for the full year 2023, compared to $53.8 million for the full year 2022.

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 1, 2024
PD, Research, SRC, Melanoma, FDA, Research and development, Immunotherapy, Food, Binimetinib, AACR, Benchmarking, Cmax, RAS, Safety, RAF, Neoplasm, Pharmacokinetics, PDAC, Administration, Paclitaxel, Patient, Clinical trial, Lung cancer, Half-life, Circulating tumor DNA, MAPK, Pancreatic cancer, Cancer, Colorectal cancer, DNA, Pharmaceutical industry

“We look forward to sharing topline data from the Phase 1 portion of the Phase 1/2a trial of IMM-1-104 this month.

Key Points: 
  • “We look forward to sharing topline data from the Phase 1 portion of the Phase 1/2a trial of IMM-1-104 this month.
  • Presented preclinical data demonstrating encouraging anti-tumor activity for IMM-1-104 and IMM-6-415: In October 2023, Immuneering presented preclinical data at AACR-NCI-EORTC.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $11.9 million compared with $9.9 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $4.4 million compared with $4.1 million for the same period of 2022.

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Retrieved on: 
Friday, March 1, 2024
NRAS, BRAF, Acquisition, SAN, KNTE, APA, SAS, Sale, Contingent value rights, RAS, RAF, Patient, Tax, Health care, Development, MEK, Lazard, Melanoma, Pharmaceutical industry

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.

Key Points: 
  • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
  • SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc .
  • (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company’s investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties.
  • In addition, Pierre Fabre Laboratories will assume up to $5 million of trade payables for the transferred assets.